youtube_live
Q3 2026 earnings • in 4 days
See detailschevron_right
EXEL:NASDAQ
Exelixis Inc
$64.53
arrow_downward
-1.19%(-0.78) 1D
$64.53
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 23, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EXEL...
Open
$65.15
High
$65.20
Low
$63.91
Mkt. cap
15.99B
Avg. vol.
2.28M
Volume
2.07M
P/E ratio
20.27
52-wk high
$65.50
52-wk low
$36.00
EPS
$3.18
Beta
0.47
Shares outstanding
247.78M
No. of employees
1K
Open
$65.15
High
$65.20
Low
$63.91
Mkt. cap
15.99B
Avg. vol.
2.28M
Volume
2.07M
P/E ratio
20.27
52-wk high
$65.50
52-wk low
$36.00
EPS
$3.18
Beta
0.47
Shares outstanding
247.78M
No. of employees
1K
News stories
From web sources and news partners
The Motley Fool
·
21 hours ago
Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy
FXEmpire
·
2 days ago
Exelixis Rises with Earnings on Tap
Yahoo Finance
·
3 days ago
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Profile
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. Wikipedia
About Exelixis Inc
CEOMichael M. Morrissey
Employees1.08K
FoundedNov 15, 1994
HeadquartersAlameda, California, United States
SectorBiotechnology
Websiteexelixis.com